vrucare
vrucare
Parakkai Solutions LLP
Bengaluru, India

Chronic kidney disease · Payor AI · India

Kidney failure is visible in claims data years before anyone reads it.

vrucare scores the claims, pharmacy and diagnosis records Indian health insurers already hold, ranks members by risk of progressing to dialysis, and reaches the ones who matter through an AI voice agent in six Indian languages.

NORMAL eGFR ≥ 90 STAGE 2 60–89 STAGE 3 30–59 STAGE 4 15–29 STAGE 5 < 15 · DIALYSIS 100 75 50 25 0 eGFR mL/min/1.73m² Yr 0 2 4 6 8 10 vrucare flags the member here ≈ 6 years of runway to slow progression Today: the payor finds out here first dialysis claim · cost locked in

Typical eGFR decline in diabetic nephropathy, ~4–6 mL/min/year untreated. Staging per KDIGO. The gap between the two markers is the entire commercial opportunity: CKD cost rises roughly 7.5× from Stage 2 to Stage 4, and around 50× once a member starts dialysis.

The gap

The most expensive avoidable claim on an Indian payor's book

128MIndians living with chronic kidney disease, most undiagnosedGBD 2023, The Lancet
₹3–6Lannual dialysis cost per patient, once it startsICMR-INDIAB
90%detected too late for cost-effective interventionUSRDS
582Minsured lives in India — the data already sits with payorsIRDAI 2025

Indian insurers already hold the signal. A pre-policy creatinine, an annual health check, a discharge summary listing three antihypertensives and metformin — the footprint of failing kidneys accumulates in payor systems for years. Nobody reads it, because nothing has been built to read Indian claims data.

How it works

Rank the book, call the member, close the loop

01 · SCORE

Risk stratification on claims-only data

A gradient-boosted model ranks every covered member by probability of progressing to dialysis, with SHAP attribution giving the medical team a readable reason for each flag. Works without lab feeds — built for the data Indian payors actually have.

02 · REACH

Voice outreach in six languages

An AI voice agent calls flagged members in English, Hindi, Tamil, Telugu, Kannada or Malayalam — explains the risk, and drives them to a creatinine test and a nephrology referral.

03 · REPORT

Conversion back to the payor

Who was called, who tested, who saw a nephrologist, and what moved. The payor sees intervention rates against the risk tiers, so the programme can be measured against claims cost rather than taken on faith.

We do not diagnose anyone. The model produces a ranked list; the creatinine test produces the diagnosis. That keeps vrucare a prioritisation layer in front of a clinician — not a medical device, and not a decision that affects anyone's coverage.

Status

Where the product actually is

Built and demonstrable

End to end, today

  • CKD risk model with SHAP explainability per feature
  • Two-tier scoring: claims-only, or lab-enriched
  • Case manager portal with risk tiers and call triggers
  • Voice agent prototype across six Indian languages
  • Full demo: claims file in, risk cohorts out, call placed

What the raise funds

Next twelve months

  • Validation on real de-identified payor data
  • Multi-horizon survival model with calibration gates
  • DPDP-compliant pipeline, audit logging, access control
  • Integration adapters for Indian TPA claim formats
  • First two paid payor pilots
Stated plainly: the model is trained on public and synthetic data and has not yet been validated on Indian payor data. No design partner is signed and there is no revenue. Securing that validation is the purpose of the raise — and the entry point we offer a payor is a free retrospective backtest on a closed book of de-identified claims, which costs them no clinical risk, no member contact and no budget.

Business model

Priced per covered life, the unit payors already budget

LineFigure
Pricing, per member per month₹5–15
Contract shapeAnnual, per covered life
Infrastructure cost at scale, monthly< $8,000
Gross margin at scale> 85%
Recurring revenue at 1,00,000 covered lives≈ ₹1.2 Cr ARR

Revenue scales with lives under management rather than claims processed, which puts vrucare on the same side as the payor and the member: every prevented progression is worth more to the insurer than the fee, and the member keeps their kidneys longer. India is the launch market — TAM across all insured lives is approximately ₹5,600 Cr, of which commercially insured lives represent roughly ₹3,200 Cr.

Why now

The rails only just arrived

  • Claims data is becoming machine-readable. NHCX under ABDM is standardising claims exchange between hospitals, insurers and TPAs on FHIR — the data stops being PDFs in a TPA folder.
  • Repricing is constrained. IRDAI has closed the old levers — no exit at renewal, pre-existing cover mandated after waiting periods, a 60-month moratorium. Cost of care is what is left.
  • Prevention is explicitly permitted. IRDAI's wellness and preventive guidelines let insurers fund exactly this kind of programme, including premium incentives for members who engage.
  • Indian-language voice became affordable. The full stack runs for under $8,000 a month, which is what makes ₹8 per member per month a viable price rather than a rounding error.

Investors

The deck, the model, and a live walkthrough are available on request.

We are raising to fund validation on real payor data and the first two paid pilots. Happy to walk through the risk model, the voice stack, or the unit economics in detail.

info@parakk.ai